Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance

Inovio Pharmaceuticals IncTrade
Vanguard Dividend Appreciation Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Vanguard Dividend Appreciation Index Fund ETF trades at $246.27. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOVIG
Market Cap
$78.55M
Sector
Health
52-Week High
$2.87$245.79
52-Week Low
$0.66$208.67
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Vanguard Dividend Appreciation Index Fund ETF

VIG trades at $246.06, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on dividend growth, with a 1.5% yield and a 20-year streak of dividend increases. Recent news highlights its appeal for long-term income investors, with top holdings like Broadcom driving performance. Support and resistance are tightly clustered around $245–$247.

Outlook remains positive for dividend growth investors, with low expense ratios and quality stock selection. Risks include interest rate sensitivity and market volatility. Analyst sentiment is favorable, emphasizing defensive positioning and long-term wealth building.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Vanguard Dividend Appreciation Index Fund ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VIG